Proceedings of the International scientific and practical conference ― Cambridge Science and Education Conference‖ (February 23-25, 2026) / Publisher website: www.naukainfo.com. – Cambridge, United Kingdom, 2026. - 289 p.

78 PGE₂: Excessive production due to COX-2 hyperactivity, stimulates fibroblasts and stromal remodeling → progression of bone marrow fibrosis, suppresses antitumor immunity (↓ NK, ↓ CD8⁺ T cells, ↑ Treg). PGF₂α: Promotes smooth muscle contraction and may participate in splenomegaly through its effect on vascular tone. PGD₂: Has immunomodulatory properties, may affect allergic and inflammatory reactions in the microenvironment. TXA₂ (thromboxane A₂): Increases the risk of thrombosis, which often complicates the course of myelofibrosis. PPGI₂ (prostacyclin): Normally counteracts thromboxanes, but its level is reduced → imbalance contributes to thrombotic complications. According to current data, the participation and importance of PG in the development of various neoplasms is more than obvious. The effect of PG in carcinogenesis depends on many factors, such as the affected tissue, the concentration of prostaglandins in plasma and their subtypes, as well as the presence of genetic mutations and different intracellular signaling pathways that tip the scales either in favor of tumor regression or cancer expansion [6]. Therefore, in-depth studies of prostaglandins involved in different cancers, as well as the different targets they modulate, as well as their role in the tumor microenvironment and the immune response, are necessary to obtain better therapeutic tools to combat cancer. REFERENCES: 1. Khoury J.D, Solary E., Abla O., Akkari Y., Alaggio R. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/ Dendritic Neoplasms. Leukemia (2022) 36:1703– 1719; URL: https://doi.org/10.1038/s41375-022-01613-1 2. Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N